1. Simvastatin treatment in subjects at high cardiovascular risk modulates AT1R expression on circulating monocytes and T lymphocytes
- Author
-
Chiara Crespi, Maria Grazia Cimpanelli, Francesca Crema, Marco Ferrari, Luigina Guasti, Sergio Lecchini, Emanuela Rasini, Laura Schembri, Ramona Consuelo Maio, Marco Cosentino, Massimiliano Legnaro, Achille Venco, Franca Marino, A. Loraschi, and Elisabetta Molteni
- Subjects
Adult ,Male ,Simvastatin ,medicine.medical_specialty ,Angiotensin receptor ,leukocytes ,Physiology ,T-Lymphocytes ,Receptor expression ,Angiotensinogen ,Polymerase Chain Reaction ,Receptor, Angiotensin, Type 2 ,Monocytes ,Receptor, Angiotensin, Type 1 ,statins ,Internal medicine ,Renin–angiotensin system ,Internal Medicine ,Humans ,Medicine ,Longitudinal Studies ,RNA, Messenger ,Receptor ,Aged ,Angiotensin II receptor type 1 ,biology ,business.industry ,Angiotensin-converting enzyme ,angiotensin ,Middle Aged ,Flow Cytometry ,Angiotensin II ,Endocrinology ,Cardiovascular Diseases ,Case-Control Studies ,biology.protein ,Female ,atherosclerosis ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Cardiology and Cardiovascular Medicine ,business ,angiotensin, atherosclerosis, leukocytes, statins ,medicine.drug - Abstract
Objective Angiotensin II, through the activation of angiotensin II type 1 receptors, plays a crucial role in atherosclerosis. Statins may interfere with the effects of angiotensin II. Methods We have investigated the expression of angiotensin II type 1 receptor, angiotensin II type 2 receptor and angiotensinogen on circulating monocytes and T-lymphocytes from subjects at high risk for vascular events before and during simvastatin treatment, and healthy controls. In-vitro experiments were also performed to assess the ability of simvastatin to interfere with angiotensin II signalling. Results In comparison with controls, high-risk subjects had similar angiotensin II type 1 receptor expression on the cell membranes but significantly higher angiotensin II type 1 receptor mRNA levels at least in monocyte subsets whereas their expression on T cells was similar. Angiotensin II type 2 receptor mRNA expression was higher than controls in both monocytes and T lymphocytes. No differences were observed in angiotensinogen expression on monocytes while T lymphocytes of high-risk subjects show higher expression. One-month treatment of high-risk subjects with simvastatin resulted in a reduction of angiotensin II type 1 receptor mRNA without affecting angiotensin II type 2 receptor whereas angiotensinogen mRNA expression was reduced at least in monocytes. Incubation in vitro with simvastatin reduces the expression of angiotensin II type 1 receptor mRNA levels on monocytes from untreated subjects. Conclusion Simvastatin induces down-regulation of the angiotensin II type 1 receptor, interferes with angiotensin II activity in immune cells and contributes to the anti-inflammatory profile of statins that can explain the therapeutic effects of these drugs.
- Published
- 2008
- Full Text
- View/download PDF